Literature DB >> 16596029

The pleiotropic effects of angiotensin receptor blockers.

Steven G Chrysant1, George S Chrysant.   

Abstract

The angiotensin receptor blockers (ARBs) are very effective and safe antihypertensive drugs. They exert their antihypertensive effect through blockage of the angiotensin II, type 1 receptor and quite possibly through stimulation by angiotensin II of the unoccupied type 2 receptor. Besides hypertension, the ARBs have been found recently to be of value in the treatment of heart failure and diabetic nephropathy. In addition, ARBs have emerged lately as being very effective and perhaps superior to other antihypertensive drugs in the prevention of de novo or recurrent strokes. Other actions that may account for their stroke-protective effects include their antiatherogenic, antidiabetic, antiplatelet aggregating, hypouricemic, and atrial antifibrillatory actions. All these actions make the ARBs a true pleiotropic class of drugs. Each of the foregoing effects will be discussed briefly in this concise review.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596029      PMCID: PMC8109722          DOI: 10.1111/j.1524-6175.2005.05264.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  59 in total

Review 1.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  S M Grundy; I J Benjamin; G L Burke; A Chait; R H Eckel; B V Howard; W Mitch; S C Smith; J R Sowers
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

2.  Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.

Authors:  F Dalmay; H Mazouz; J Allard; F Pesteil; J M Achard; A Fournier
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2001-06       Impact factor: 1.636

3.  Chymase-dependent angiotensin II formation in human vascular tissue.

Authors:  S Takai; D Jin; M Sakaguchi; M Miyazaki
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.

Authors:  R Butler; A D Morris; J J Belch; A Hill; A D Struthers
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

Review 5.  Angiotensin II and the endothelium: diverse signals and effects.

Authors:  Tetsu Watanabe; Thomas A Barker; Bradford C Berk
Journal:  Hypertension       Date:  2005-01-03       Impact factor: 10.190

6.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Authors:  Kenneth Dickstein; John Kjekshus
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

7.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

Authors:  Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Alberto Volpi; Yann-Tong Chiang; Raymond L Benza; Sidney O Gottlieb; Thomas D Kleemann; Franco Rosconi; Pieter M Vandervoort; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

8.  Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Authors:  Stephen C Benson; Harrihar A Pershadsingh; Christopher I Ho; Amar Chittiboyina; Prashant Desai; Michal Pravenec; Nianning Qi; Jiaming Wang; Mitchell A Avery; Theodore W Kurtz
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

9.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study.

Authors:  Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf De Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

10.  Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells.

Authors:  P De Paolis; A Porcellini; B Gigante; R Giliberti; A Lombardi; C Savoia; S Rubattu; M Volpe
Journal:  J Hypertens       Date:  1999-12       Impact factor: 4.844

View more
  21 in total

Review 1.  Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

2.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 3.  Inhibiting the renin-angiotensin system with ACE Inhibitors or ARBs after MI.

Authors:  Maryse Palardy; Anique Ducharme; Eileen O'Meara
Journal:  Curr Heart Fail Rep       Date:  2007-12

4.  Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study.

Authors:  J Castillo; J Alvarez-Sabín; E Martínez-Vila; J Montaner; T Sobrino; J Vivancos
Journal:  J Neurol       Date:  2009-02-27       Impact factor: 4.849

Review 5.  Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Authors:  Addison A Taylor; Helmy Siragy; Shawna Nesbitt
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

6.  The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.

Authors:  Ihab Hajjar; Meaghan Hart; William Milberg; Vera Novak; Lewis Lipsitz
Journal:  BMC Geriatr       Date:  2009-11-18       Impact factor: 3.921

Review 7.  Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks".

Authors:  Niki Katsiki; Konstantinos Tsioufis; Dilek Ural; Massimo Volpe
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-06-15       Impact factor: 3.738

8.  Initial combination therapy compared with monotherapy in diabetic hypertensive patients.

Authors:  James R Sowers; Guido Lastra; Ricardo Rocha; Yodit Seifu; Nora Crikelair; Drew G Levy
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

Review 9.  An update on the cardiovascular pleiotropic effects of milk and milk products.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

10.  Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.

Authors:  Steven G Chrysant
Journal:  Drugs R D       Date:  2012-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.